ReviewMolecular neurobiology2016
Resveratrol Protects from Toxin-Induced Parkinsonism: Plethora of Proofs Hitherto Petty Translational Value.
Review in Molecular neurobiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- UPLC-QToF-MS/MS screening and characterization of3 Biotech · 2024Article
- Plausible Role of Mitochondrial DNA Copy Number in Neurodegeneration-a Need for Therapeutic Approach in Parkinson's Disease (PD).Molecular neurobiology · 2023Review
- The Role of PGC-1α-Mediated Mitochondrial Biogenesis in Neurons.Neurochemical research · 2023Review
- Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems.Pharmaceutics · 2022Review
- Dopaminergic Axons: Key Recitalists in Parkinson's Disease.Neurochemical research · 2022Review
- Separation and Identification of Resveratrol Butyrate Ester Complexes and Their Bioactivity in HepG2 Cell Models.International journal of molecular sciences · 2021Article
- Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.Acta pharmaceutica Sinica. B · 2021Review
- Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring Rats by Modulating Antioxidant Capacity and Gut Microbiota.International journal of molecular sciences · 2021Article
- PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders.Pharmacology & therapeutics · 2021Review
- In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons.Frontiers in cell and developmental biology · 2020Review
- Phytochemicals Bridging Autophagy Induction and Alpha-Synuclein Degradation in Parkinsonism.International journal of molecular sciences · 2019Review
- Cypermethrin Activates Autophagosome Formation Albeit Inhibits Autophagy Owing to Poor Lysosome Quality: Relevance to Parkinson's Disease.Neurotoxicity research · 2018Article
- Plant Extracts and Phytochemicals TargetingFrontiers in pharmacology · 2018Review
- Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.Neurochemical research · 2017Review
- Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.Molecular neurobiology · 2017Review
- Neuronal Nitric Oxide Synthase Negatively Regulates Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration.Molecular neurobiology · 2017Article
- Carnosic acid protects non-alcoholic fatty liver-induced dopaminergic neuron injury in rats.Metabolic brain disease · 2017Article
- Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.Molecular neurodegeneration · 2017Review
- Ibuprofen abates cypermethrin-induced expression of pro-inflammatory mediators and mitogen-activated protein kinases and averts the nigrostriatal dopaminergic neurodegeneration.Molecular neurobiology · 2016Article
- Association of Polymorphism of Neuronal Nitric Oxide Synthase Gene with Risk to Parkinson's Disease.Molecular neurobiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a mysterious, chronic, multi-factorial and progressive disorder of the nervous system that is characterized by the selective loss of dopamine-producing cells of the substantia nigra leading to dopamine deficiency in the striatum. PD is exemplified by oxidative stress, α-synuclein accumulation, mitochondrial dysfunction, defective ubiquitin proteasome system, aberrant autophagy, inflammation, and atypical apoptosis, which eventually lead to slowness of movement, resting tremor, stiffness, and loss of balance. Despite incomprehensible etiology, timely diagnosis, and permanent cure, a handful of synthetic and natural agents rescue from the symptomatic features and delay disease progression. At low doses, a natural polyphenol, trans-3,5,4'-trihydroxystilbene (resveratrol), delays neurodegeneration in the cellular and animal models and lessens oxidative stress, mitochondrial dysfunction, aberrant apoptosis, and defective autophagy. The present article explains neuroprotective efficacy, advantages, and downsides of resveratrol in the conventional and preclinical models. This piece of writing also examines its probable neuroprotective mechanisms and constraints of realistic recital in clinical investigations and likely endeavors to minimize apprehensions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.